Dave Mason - HLS Therapeutics Investor Officer
| HLS Stock | CAD 3.41 0.04 1.16% |
Executive
Dave Mason is Investor Officer of HLS Therapeutics
| Address | 10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2 |
| Phone | 647 495 9000 |
| Web | https://www.hlstherapeutics.com |
HLS Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0274) % which means that it has lost $0.0274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2433) %, meaning that it generated substantial loss on money invested by shareholders. HLS Therapeutics' management efficiency ratios could be used to measure how well HLS Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to grow to -0.56. In addition to that, Return On Capital Employed is likely to grow to -0.05. At this time, HLS Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 11th of December 2024, Intangible Assets is likely to grow to about 173.4 M, while Total Assets are likely to drop about 114 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD FCAP | Medicenna Therapeutics Corp | N/A | |
| Thomas MBA | Profound Medical Corp | N/A | |
| Abbey Goodman | Profound Medical Corp | 41 | |
| Jacques Cornet | Profound Medical Corp | 68 | |
| Monica Percario | Knight Therapeutics | N/A | |
| Henrique Dias | Knight Therapeutics | N/A | |
| Marc Wiles | Aptose Biosciences | N/A | |
| CBV CA | Medicenna Therapeutics Corp | 51 | |
| Stephani Saverio | Knight Therapeutics | N/A | |
| Philippe Ledru | Aptose Biosciences | 56 | |
| Susan Emblem | Knight Therapeutics | N/A | |
| Roger BSc | Aptose Biosciences | N/A | |
| Mathieu Burtnyk | Profound Medical Corp | 42 | |
| Hartmut Warnken | Profound Medical Corp | 51 | |
| Melanie Groleau | Knight Therapeutics | N/A | |
| Rafael MD | Aptose Biosciences | 52 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0274 |
HLS Therapeutics Leadership Team
Elected by the shareholders, the HLS Therapeutics' board of directors comprises two types of representatives: HLS Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLS. The board's role is to monitor HLS Therapeutics' management team and ensure that shareholders' interests are well served. HLS Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HLS Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA LLB, CoFounder Chairman | ||
| Brian Walsh, Senior Commercial | ||
| Sanjiv Sharma, Chief Officer | ||
| JD BA, HR Legal | ||
| David Spence, Co Controller | ||
| CPA CGA, Interim Director | ||
| Jason PharmD, Vice Affairs | ||
| Gilbert Godin, CEO CoFounder | ||
| Tim MBA, Chief Officer | ||
| Dave Mason, Investor Officer | ||
| John Hanna, Interim Director | ||
| Craig MBA, CEO Director |
HLS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HLS Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 181.96 M | ||||
| Shares Outstanding | 31.79 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 65.10 % | ||||
| Number Of Shares Shorted | 4.64 K | ||||
| Price To Book | 0.96 X |
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.